Literature DB >> 15601761

Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats.

Jonathan J Li1, S John Weroha, Wilma L Lingle, Dan Papa, Jeffrey L Salisbury, Sara Antonia Li.   

Abstract

Estrogens play a crucial role in the causation and development of sporadic human breast cancer (BC). Chromosomal instability (CIN) is a defining trait of early human ductal carcinoma in situ (DCIS) and is believed to precipitate breast oncogenesis. We reported earlier that 100% of female ACI (August/Copenhagen/Irish) rats treated with essentially physiological serum levels of 17beta-estradiol lead to mammary gland tumors with histopathologic, cellular, molecular, and ploidy changes remarkably similar to those seen in human DCIS and invasive sporadic ductal BC. Aurora-A (Aur-A), a centrosome kinase, and centrosome amplification have been implicated in the origin of aneuploidy via CIN. After 4 mo of estradiol treatment, levels of Aur-A and centrosomal proteins, gamma-tubulin and centrin, rose significantly in female ACI rat mammary glands and remained elevated in mammary tumors at 5-6 mo of estrogen treatment. Centrosome amplification was initially detected at 3 mo of treatment in focal dysplasias, before DCIS. At 5-6 mo, 90% of the mammary tumor centrosomes were amplified. Comparative genomic hybridization revealed nonrandom amplified chromosome regions in seven chromosomes with a frequency of 55-82% in 11 primary tumors each from individual rats. Thus, we report that estrogen is causally linked via estrogen receptor alpha to Aur-A overexpression, centrosome amplification, CIN, and aneuploidy leading to BC in susceptible mammary gland cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15601761      PMCID: PMC539804          DOI: 10.1073/pnas.0408273101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

Review 1.  Estrogen and the risk of breast cancer.

Authors:  M Clemons; P Goss
Journal:  N Engl J Med       Date:  2001-01-25       Impact factor: 91.245

Review 2.  Mitotic kinases as regulators of cell division and its checkpoints.

Authors:  E A Nigg
Journal:  Nat Rev Mol Cell Biol       Date:  2001-01       Impact factor: 94.444

3.  Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues.

Authors:  G S Chetrite; J Cortes-Prieto; J C Philippe; F Wright; J R Pasqualini
Journal:  J Steroid Biochem Mol Biol       Date:  2000 Jan-Feb       Impact factor: 4.292

Review 4.  Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase.

Authors:  N E Hynes; H A Lane
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

5.  Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers.

Authors:  Y Miyoshi; K Iwao; C Egawa; S Noguchi
Journal:  Int J Cancer       Date:  2001-05-01       Impact factor: 7.396

6.  Unusual deregulation of cell cycle components in early and frank estrogen-induced renal neoplasias in the Syrian hamster.

Authors:  D Z Liao; X Hou; S Bai; S A Li; J J Li
Journal:  Carcinogenesis       Date:  2000-12       Impact factor: 4.944

7.  Overexpression and amplification of c-myc in the Syrian hamster kidney during estrogen carcinogenesis: a probable critical role in neoplastic transformation.

Authors:  J J Li; X Hou; S K Banerjee; D Z Liao; F Maggouta; J S Norris; S A Li
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

Review 8.  The contribution of epigenetic changes to abnormal centrosomes and genomic instability in breast cancer.

Authors:  J L Salisbury
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-04       Impact factor: 2.673

9.  Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women.

Authors:  C I Li; N S Weiss; J L Stanford; J R Daling
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

10.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance.

Authors:  S L Deming; S J Nass; R B Dickson; B J Trock
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more
  62 in total

Review 1.  Estrogen and ERalpha: culprits in cervical cancer?

Authors:  Sang-Hyuk Chung; Silvia Franceschi; Paul F Lambert
Journal:  Trends Endocrinol Metab       Date:  2010-04-22       Impact factor: 12.015

2.  Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Jingqin Luo; Simon Coetzee; Omar Khalid; Benjamin P Berman; Debu Tripathy; Matthew J Ellis; Baruch Frenkel
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

3.  DNA content and chromatin texture of human breast epithelial cells transformed with 17-beta-estradiol and the estrogen antagonist ICI 182,780 as assessed by image analysis.

Authors:  Maria Luiza S Mello; Benedicto C Vidal; Irma H Russo; Mohamed H Lareef; Jose Russo
Journal:  Mutat Res       Date:  2007-01-08       Impact factor: 2.433

4.  A G-quadruplex stabilizer induces M-phase cell cycle arrest.

Authors:  Yuan-Chin Tsai; Haiyan Qi; Chao-Po Lin; Ren-Kuo Lin; John E Kerrigan; Suzanne G Rzuczek; Edmond J LaVoie; Joseph E Rice; Daniel S Pilch; Yi Lisa Lyu; Leroy F Liu
Journal:  J Biol Chem       Date:  2009-06-16       Impact factor: 5.157

Review 5.  Centrosome amplification: a suspect in breast cancer and racial disparities.

Authors:  Angela Ogden; Padmashree C G Rida; Ritu Aneja
Journal:  Endocr Relat Cancer       Date:  2017-05-17       Impact factor: 5.678

6.  MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis.

Authors:  Bhupendra Singh; Amruta M Ronghe; Anwesha Chatterjee; Nimee K Bhat; Hari K Bhat
Journal:  Carcinogenesis       Date:  2013-03-14       Impact factor: 4.944

7.  Differential expression of centrosomal proteins at different stages of human glioma.

Authors:  Joon-Khim Loh; Ann-Shung Lieu; Chia-Hua Chou; Fang-Yi Lin; Chia-Hung Wu; Sheng-Long Howng; Chung-Ching Chio; Yi-Ren Hong
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

8.  A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention.

Authors:  Nina Korzeniewski; Sarah Wheeler; Payel Chatterjee; Anette Duensing; Stefan Duensing
Journal:  Mol Cancer       Date:  2010-06-17       Impact factor: 27.401

9.  The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

Authors:  Hirokuni Ikeda; Naruto Taira; Fumikata Hara; Takeo Fujita; Hiromasa Yamamoto; Junichi Soh; Shinichi Toyooka; Tomohiro Nogami; Tadahiko Shien; Hiroyoshi Doihara; Shinichiro Miyoshi
Journal:  Breast Cancer Res       Date:  2010-06-28       Impact factor: 6.466

10.  Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats.

Authors:  Edward W Blank; Po-Yin Wong; Rajkumar Lakshmanaswamy; Raphael Guzman; Satyabrata Nandi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.